• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乙型肝炎相关肝细胞癌的复发与切除时的高病毒载量有关。

Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection.

作者信息

Hung Ivan F N, Poon Ronnie T P, Lai Ching-Lung, Fung James, Fan Sheung-Tat, Yuen Man-Fung

机构信息

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

出版信息

Am J Gastroenterol. 2008 Jul;103(7):1663-73. doi: 10.1111/j.1572-0241.2008.01872.x. Epub 2008 Jul 4.

DOI:10.1111/j.1572-0241.2008.01872.x
PMID:18616655
Abstract

BACKGROUND/AIMS: To identify the risk factors for recurrence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after resection.

METHODS

Seventy-two patients who underwent liver resection for HBV-related HCC were recruited. Demographic, biochemical, tumor, and viral factors at the time of resection were evaluated by univariate and multivariate analyses to identify risk factors associated with recurrence after resection.

RESULTS

The median follow-up period was 18.9 months and the median age was 53 yr, with male-to-female ratio of 59:13. Age >60 yr, tumor size >5 cm, poorly differentiated tumor, lymphovascular permeation, the presence of microsatellite lesions, alpha-fetoprotein (AFP) level >1,000 ng/mL and HBV viral load >2,000 IU/mL (4 log(10) copies/mL) at the time of tumor resection, HBV genotype C, core promoter mutations, and patients with no antiviral treatment after tumor resection were associated with increased cumulative risk of HCC recurrence. By multivariate analysis, HBV viral load >2,000 IU/mL (4 log(10) copies/mL) (P= 0.001, odds ratio [OR] 22.3), AFP >1,000 ng/mL (P= 0.02, OR 7.4), tumor size >5 cm (P= 0.02, OR 5.1), and age >60 yr (P= 0.01, OR 4) at the time of tumor resection remained to be the independent risk factors.

CONCLUSIONS

Viral load of >2,000 IU/mL (4 log(10) copies/mL) is the most important correctable risk factor for HCC recurrence after resection. Whether antiviral therapy in these patients can decrease tumor recurrence requires further investigations.

摘要

背景/目的:确定乙型肝炎病毒(HBV)相关肝细胞癌(HCC)切除术后复发的危险因素。

方法

招募72例行肝切除术治疗HBV相关HCC的患者。通过单因素和多因素分析评估切除时的人口统计学、生化、肿瘤和病毒学因素,以确定与切除术后复发相关的危险因素。

结果

中位随访期为18.9个月,中位年龄为53岁,男女比例为59:13。年龄>60岁、肿瘤大小>5 cm、肿瘤低分化、淋巴管浸润、存在微卫星灶、肿瘤切除时甲胎蛋白(AFP)水平>1000 ng/mL和HBV病毒载量>2000 IU/mL(4 log₁₀拷贝/mL)、HBV基因型C、核心启动子突变以及肿瘤切除后未进行抗病毒治疗的患者,HCC复发的累积风险增加。多因素分析显示,肿瘤切除时HBV病毒载量>2000 IU/mL(4 log₁₀拷贝/mL)(P = 0.001,比值比[OR] 22.3)、AFP>1000 ng/mL(P = 0.02,OR 7.4)、肿瘤大小>5 cm(P = 0.02,OR 5.1)和年龄>60岁(P = 0.01,OR 4)仍是独立危险因素。

结论

病毒载量>2000 IU/mL(4 log₁₀拷贝/mL)是切除术后HCC复发最重要的可纠正危险因素。这些患者进行抗病毒治疗是否能降低肿瘤复发尚需进一步研究。

相似文献

1
Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection.乙型肝炎相关肝细胞癌的复发与切除时的高病毒载量有关。
Am J Gastroenterol. 2008 Jul;103(7):1663-73. doi: 10.1111/j.1572-0241.2008.01872.x. Epub 2008 Jul 4.
2
Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.乙型肝炎包膜抗原阴性预测乙型肝炎病毒相关肝细胞癌消融治疗后肝内复发。
J Gastroenterol Hepatol. 2011 Nov;26(11):1638-45. doi: 10.1111/j.1440-1746.2011.06777.x.
3
The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence.接受经动脉化疗栓塞术的肝细胞癌患者中,乙肝病毒载量对完全坏死术后复发的影响:对病毒抑制以降低癌症复发风险的意义。
Cancer. 2007 Oct 15;110(8):1760-7. doi: 10.1002/cncr.22984.
4
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.乙肝相关性肝细胞癌早期及晚期复发的危险因素。
J Hepatol. 2009 Nov;51(5):890-7. doi: 10.1016/j.jhep.2009.07.009. Epub 2009 Jul 23.
5
Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area.乙型肝炎病毒基因混合体、C2和B2亚基因型在肝细胞癌中的作用:与同一地区慢性乙型肝炎和无症状携带者状态的比较。
Carcinogenesis. 2008 Sep;29(9):1685-91. doi: 10.1093/carcin/bgm301. Epub 2008 Jan 12.
6
High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study.高病毒载量与乙肝病毒相关肝细胞癌根治性切除术后总体生存率及无复发生存率低相关:一项前瞻性队列研究
Eur J Surg Oncol. 2012 Aug;38(8):683-91. doi: 10.1016/j.ejso.2012.04.010. Epub 2012 May 22.
7
High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma.血清透明质酸和 HBV 病毒载量高是乙型肝炎相关小肝细胞癌完全射频消融后局部复发的主要预后因素。
Ann Surg Oncol. 2012 Apr;19(4):1284-91. doi: 10.1245/s10434-011-2042-3. Epub 2011 Sep 13.
8
Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.隐匿性乙型肝炎病毒感染和既往乙型肝炎病毒感染对丙型肝炎病毒所致肝硬化患者肝细胞癌发生的影响
Scand J Gastroenterol. 2008;43(7):849-56. doi: 10.1080/00365520801935459.
9
Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma.乙型肝炎病毒相关肝细胞癌年轻患者的血清病毒载量较低。
J Viral Hepat. 2007 Mar;14(3):153-60. doi: 10.1111/j.1365-2893.2006.00780.x.
10
High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma.高病毒载量和乙型肝炎病毒C基因型e亚型与肝细胞癌风险增加相关。
J Clin Oncol. 2008 Jan 10;26(2):177-82. doi: 10.1200/JCO.2007.13.2043.

引用本文的文献

1
Tenofovir disoproxil fumarate versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis.替诺福韦酯与恩替卡韦对乙型肝炎病毒相关肝细胞癌手术切除后预后的影响:一项系统评价和荟萃分析
Front Oncol. 2025 May 27;15:1462794. doi: 10.3389/fonc.2025.1462794. eCollection 2025.
2
Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update.《中国肝细胞癌新辅助及转化治疗专家共识:2023年更新》
Liver Cancer. 2024 Sep 3;14(2):223-238. doi: 10.1159/000541249. eCollection 2025 Apr.
3
Association Between Viral Replication Activity and Postoperative Recurrence of HBV-Related Hepatocellular Carcinoma.
病毒复制活性与乙型肝炎病毒相关肝细胞癌术后复发之间的关联
Aliment Pharmacol Ther. 2025 May;61(10):1680-1691. doi: 10.1111/apt.70085. Epub 2025 Mar 16.
4
Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity.HBV 相关 HCC 经治愈性治疗后,无论 HBV 复制活性如何,均有相似的复发。
PLoS One. 2024 Aug 26;19(8):e0307712. doi: 10.1371/journal.pone.0307712. eCollection 2024.
5
A Review of the Systemic Manifestations of Hepatitis B Virus Infection, Hepatitis D Virus, Hepatocellular Carcinoma, and Emerging Therapies.乙型肝炎病毒感染、丁型肝炎病毒、肝细胞癌及新兴疗法的全身表现综述
Gastro Hep Adv. 2023 Jul 17;3(2):276-291. doi: 10.1016/j.gastha.2023.06.014. eCollection 2024.
6
Perioperative remedial antiviral therapy in hepatitis B virus-related hepatocellular carcinoma resection: How to achieve a better outcome.乙型肝炎病毒相关肝细胞癌切除术中的围手术期补救性抗病毒治疗:如何取得更好的疗效。
World J Gastrointest Oncol. 2024 May 15;16(5):1833-1848. doi: 10.4251/wjgo.v16.i5.1833.
7
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.英国胃肠病学会成人肝细胞癌管理指南。
Gut. 2024 Jul 11;73(8):1235-1268. doi: 10.1136/gutjnl-2023-331695.
8
Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma.术前抗病毒治疗对乙型肝炎病毒相关肝细胞癌预后的影响。
BMC Cancer. 2024 Mar 4;24(1):291. doi: 10.1186/s12885-024-12031-0.
9
The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.替诺福韦与恩替卡韦维持治疗对手术后肝细胞癌复发的影响(SWITE):一项随机对照试验的研究方案。
Trials. 2023 Dec 2;24(1):781. doi: 10.1186/s13063-023-07822-y.
10
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.《2022年韩国肝脏癌协会-韩国国立癌症中心肝细胞癌管理实践指南》
J Liver Cancer. 2023 Mar;23(1):1-120. doi: 10.17998/jlc.2022.11.07. Epub 2022 Dec 9.